Skip to main content

Table 3 28-day PCR corrected treatment outcomes: WHO algorithm

From: Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers

PCR adjusted Outcome

Artesunate–amodiaquine

Artemether–lumefantrine

Bensonville (n = 91)

Saclepea (n = 89)

Overall (n = 180)

Kakata (N = 89)

Sinje (N = 90)

Overall (n = 179)

n (%)

CI 95%

n (%)

95% CI

% (CI 95%)

n (%)

CI 95%

n (%)

95% CI

% (CI 95%)

LCFa

0

0.0–7.1

2 (2.4)

0.3–8.5

1.5 (0.2–5.3)

0

0.0–4.6

0 (0)

0.0–4.1

0 (0.0–2.2

LPFb

5 (9.8)

3.3–21.4

4 (4.9)

1.3

7.5 (3.6–13.3)

0

0.0–4.6

0 (0)

0.0–4.1

0 (0.0–2.2

ACPRc

46 (90.2)

78.6–96.7

76 (92.7)

84.8–97.3

91.0 (84.9–95.3)

79 (100)

95.4–100

88 (100)

95.9–100

100 (97.8–100)

Total per-protocol

51

 

82

 

134

79

 

88

 

167

Withdrawn/lost:

19 (20.9)

 

1 (1.1)

 

20 (11.1)

5 (5.6)

 

2 (2.2)

 

7 (3.9)

Re-infection

20 (23.1)

 

5 (5.6)

 

25 (13.9)

5 (5.6)

 

0

 

5

Unknown

1 (1.1)

 

0

 

1 (0.6)

0

 

0

 

0

KMd cure rate

92.1

81.9–96.6

93.0

85.1–96.8

92.0 (86.4–95.4)

100

NA

100

NA

100 (NA)

  1. a LCF late clinical failure, bLPF late parasitological failure, cACPR adequate clinical and parasitological response, dKM Kaplan Meier